Group Members:Group Members:Md.MushfiqMd.Mushfiq

Iqbal HossainIqbal Hossain

Shapar NewazShapar Newaz

Tasvir A R ChowdhuryTasvir A R Chowdhury

Largest exporters of medicine in BangladeshLargest exporters of medicine in Bangladesh A local company with a global visionA local company with a global vision

- - An emerging globally competitive industryAn emerging globally competitive industry

Beximco boasts world-class facilitiesBeximco boasts world-class facilities Core Values of Beximco Pharmaceuticals Core Values of Beximco Pharmaceuticals

- some Key Facts- some Key Facts

New product and service offerings & New product and service offerings & international recognitioninternational recognition

Research & Development: key to global Research & Development: key to global competencecompetence

Beximco - Staying ahead of the game Beximco - Staying ahead of the game - some statistical data- some statistical data

Competitive Advantages and the ways it changes over time: Distinguished operational capability

In 1980 it was small in operation but big in dreams and passionate with its vision - building a healthier tomorrow where people will live longer, healthier and happier. Its activities have always been centered on developing core competencies to deliver the best in the industry ensuring superior value and return to customers.

Consistently delivering high quality products

Today, the name “Beximco Pharma” has become synonymous with ‘trust’ and ‘reliability’. Quality is its relentless passion. Quality is ingrained in our values and in all that it does. Beximco Pharma’s business processes and practices are designed to achieve quality results that would meet the expectations of patients and physicians by getting the highest quality products, and of shareholders and stakeholders through achieving returns.

Professional Management CapabilityBeximco Pharma is the pioneer in implementing corporate governance to professionally run a company in Bangladesh. Beximco Pharma provides an environment which fosters creativity, innovation, self-development and entrepreneurship.

Adopting innovation in manufacturing process Beximco Pharma has always been the pioneer in adopting innovative technologies that introduced both sophistication and scale in our business processes. It also focuses on improving manufacturing efficiency to meet the challenge of maintaining the bottom line of the business in an ever-changing competitive market place.

R&D capability in both formulation and API (Active Pharmaceutical Ingredients)

R&D is another area where Beximco Pharma has already shown capability and led the Bangladesh Pharmaceutical Market in both formulation R&D and API R&D. Its formulation R&D capability is proven not only by the consistent quality of its products but also by its ability to introduce hi-tech, specialized products and dosage forms. The reverse engineering capability of the R&D team has enabled it to introduce innovative new products to serve the ailing people at home and abroad.

Sales & Marketing capability focused on brand building

The major source of competitive advantages of Beximco Pharma is its sales and marketing team. Its marketing team is composed of innovative people from diverse discipline. Because of the innovative & creative approach adopted by its marketing team, it has been able to create many vibrant brands like Napa, Neoceptin-R, Amdocal, Neofloxin, Tycil, Omastin, Azmasol, Bexitrol-F, Atova, Bextram Gold etc. Infact, the ability of its sales & marketing team to differentiate our brands even in a crowded generic market is Beximco Pharma’s major competitive advantage.

Experience in foreign markets

Beximco Pharma always took the leading, proactive and pioneering role in exporting pharmaceuticals from Bangladesh

It is the pioneer in exporting APIs, IV Fluids and hi-tech specialized products.

It is the first pharmaceutical company in Bangladesh to enter CIS countries.

It is also pioneer to enter African markets. It is the only company in Bangladesh to supply medicines

to Raffles Hospital and KK Women & Children Hospital of Singapore.

It is the only company in Bangladesh to supply medicines to Raffles Hospital and KK Women & Children Hospital of Singapore.

Future growth potential Domestic and existing export markets

Its past and present performances clearly suggest that it has ample scope to grow even in the domestic as well as in our existing export markets.

Beximco Pharma has already identified some attractive niche markets where the investment is negligible as compared to its expected returns in terms of profitability. Once the new OSD (Oral Solide Dosage) plant is operational and it has the capacity, confidently, it will be able to capitalize on these opportunities and increase its market share in the domestic market as well as in other existing export markets.

New export markets

Each year patents on pharmaceutical products expire with annual sales worth billions of dollars. Data monitor estimates that there are blockbuster drugs coming off-patent by 2007 which have sales in excess of US $82 billion. This will be one of the key factors which will help drive generic pharmaceutical growth over the next decade. Beximco Pharma is seeking for position to take advantage of this growing generic market by regularly introducing new products in its existing and new markets. Its low manufacturing cost will provide a competitive edge over our global competitors in any international generic pharmaceutical market.

Contract Manufacturing Cost of medication is becoming a major concern even in the developed countries. This particular issue coupled with severe price competition from the generic manufacturers has prompted a number of giant multinational companies to shift or outsource their production from developed to developing and less developed countries, because of huge cost advantage. It is believed that the world pharmaceutical market will continue to see more consolidation than ever across the entire value chain of the pharmaceutical business. Big companies will continue to look for suitable partners in their supply chain management in order to reduce their cost of production.

Beximco Pharma has always operated like a ‘multinational’ in terms of professionalism and infrastructure so as to build the platform to become a global player. Management has adhered to international regulatory standards which is more preferable to our international partners.

Sales Growth Rate

Growth Rates (%) 2008 2007 2006 2005 2004 STDEV

Sales 14.23217 -2.84395 11.28017 38.47012 10.02235 17.3734379

Fixed Asset 11.23766 5.54667 14.83951 20.40813 4.156333 7.737429242

Operating Cost 28.23258 -0.99797 18.03202 78.44515 17.45111 34.62185398

Current Asset 10.95183 -12.9153 -3.96058 41.4457 19.23751 24.43050677

Retained Earning 16.64884 3.786453 16.55193 41.04439 5.212577 17.23738

Share Price 24.30525 9.683426 -7.09343 -37.2421 131.8731 74.29356

Non-current Liability 1.624435 44.54765 -11.5582 -23.4905 -3.00112 29.82361

Current Liability 12.70519 -35.5876 1.023103 47.03386 38.35137 37.88072

EPS 8.428821 -25.0608 -35.3774 35.03185 59.12162 45.89124

Pro Forma Statements - Income2007 2008 2009 2010 2011 2112

1 Net Sales Revenue 3,597,024,812 4,108,881,443 4,693,575,272 5,361,471,033 6,124,408,361 6,995,911,671

2 Cost of Goods Sold (1,967,509,975) (2,247,486,644) (2,567,303,994) (2,932,631,352) (3,349,944,794) (3,826,641,938)

3 Gross Profit (2-1)1,629,514,837 1,861,394,798 2,126,271,278 2,428,839,681 2,774,463,568 3,169,269,733

4 Administrative Expenses (145,544,701) (166,255,712) (189,913,900) (216,938,648) (247,809,017) (283,072,240)

5 Selling, Marketing and Distribution Expenses

(829,191,989) (947,186,009) (1,081,970,578) (1,235,934,991) (1,411,808,541) (1,612,708,896)

6 Operating Expenses(974,736,690) (1,113,441,721) (1,271,884,478) (1,452,873,639) (1,659,617,558) (1,895,781,136)

7 Profit from Operations 654,778,147 747,953,077 854,386,800 975,966,042 1,114,846,010 1,273,488,597

8 Other Income 19,625,795 22,418,546 25,608,705 29,252,823 33,415,500 38,170,526

9 Finance Cost (254,742,392) (290,992,234) (332,400,429) (379,701,010) (433,732,464) (495,452,594)

10 Profit Before Contribution to WPPF419,661,550 479,379,389 547,595,076 625,517,855 714,529,046 816,206,529

11 Contribution to Workers' Profit Participation/ Welfare

Funds (19,983,883) (22,827,590) (26,075,956) (29,786,564) (34,025,192) (38,866,977)

12 Profit Before Tax 399,677,667 456,551,799 521,519,120 595,731,291 680,503,853 777,339,552

13 Current Tax (57,661,278) (65,866,478) (75,239,278) (85,945,827) (98,175,918) (112,146,351)

14 Deferred Tax Income/(Expense) 11,051,489 12,624,116 14,420,528 16,472,569 18,816,615 21,494,220

15 Income Tax Expense(46,609,789) (53,242,362) (60,818,750) (69,473,258) (79,359,303) (90,652,132)

16 Profit After Tax Transferred to Statement of Changes in

Equity 353,067,878 403,309,437 460,700,370 526,258,033 601,144,551 686,687,420

17Earnings Per Share (of TK. 10 /- each)

3.08 3.52 4.02 4.60 5.25 6.00

18Number of shares used to compute EPS

114,507,043 114,507,043 114,507,043 114,507,043 114,507,043 114,507,043

19Dividend (156,145,966) (178,365,537) (203,746,953) (232,740,144) (265,859,067) (303,690,812)

20Provided Tax (47,520,125) (54,282,239) (62,006,601) (70,830,141) (80,909,270) (92,422,659)

21Retain Earning 149,401,787 170,661,661 194,946,816 222,687,748 254,376,214 290,573,949

2007 2008 2009 2010 2011 2012

(Growth Rate = 14.23%)

Fixed Assets 9,029,643,482 10,314,561,749 11,782,323,886 13,458,948,575 15,374,156,958 17,561,899,493

Current Assets 2,923,775,458 3,339,828,706 3,815,086,330 4,357,973,115 4,978,112,690 5,686,498,125

Total Assets 11,953,418,940 13,654,390,455 15,597,410,217 17,816,921,691 20,352,269,647 23,248,397,618

Non-Current Liabilities 2,074,506,357 2,369,708,612 2,706,918,147 3,092,112,599 3,532,120,222 4,034,740,930

Current Liabilities 1,627,972,936 1,859,633,485 2,124,259,330 2,426,541,432 2,771,838,278 3,166,270,865

Total Liabilities 3,702,479,293 4,229,342,096 4,831,177,477 5,518,654,032 6,303,958,500 7,201,011,795

Share Premium 1,489,750,000 1,489,750,000 1,489,750,000 1,489,750,000 1,489,750,000 1,489,750,000

Excess of Issue Price over Face Value of GDRs 1,689,636,958 1,689,636,958 1,689,636,958 1,689,636,958 1,689,636,958 1,689,636,958

Capital Reserve on Merger 294,950,950 294,950,950 294,950,950 294,950,950 294,950,950 294,950,950

Tax-Holiday Reserve 442,354,953 505,302,063 577,206,546 659,343,038 753,167,552 860,343,295

Retained Earning 3,189,176,356 3,642,996,151 4,161,394,504 4,753,560,942 5,429,992,664 6,202,680,620

Issued Share Capital 1,145,070,430 1,308,013,952 1,494,144,338 1,706,761,077 1,949,633,178 2,227,065,979

Shareholders' Equity 8,250,939,647 8,930,650,074 9,707,083,296 10,594,002,964 11,607,131,302 12,764,427,802

Shareholders' Equity & Liabilities 11,953,418,940 13,159,992,171 14,538,260,772 16,112,656,996 17,911,089,802 19,965,439,597

Excess(Required) Fund 0 (494,398,284) (1,059,149,444) (1,704,264,695) (2,441,179,845) (3,282,958,021)

Pro Forma balance sheet

Bangladesh's largest Pharmaceutical Companies (by sales '08)

Top 10 Sales in $ Mn

Square $138.7

Incepta $ 52.1

Beximco $ 49.0

Acme $ 36.3

Eskayef $ 32.1

ACI $ 31.3

Opsonin $ 29.7

Renata $ 29.1

Aristopharma $ 28.8

Drug International $ 23.4

Market Shares

Sponsors and Directors of BPL have 20.63%, Other financial and non financial Institutes

have 11.25%, Foreign investors have 33.45% Public have 34.67% of shares of the company.

Company Shares

“On July 22, 2008 Beximco Pharmaceuticals Ltd. (‘BPL’ or the ‘Company’), the leading Bangladeshi pharmaceutical manufacturer and exporter, is pleased to announce that it has received approval (GMP Clearance) from Therapeutic Goods Administration (TGA), Australia for its new Oral Solid Dosage (Tablet, Capsule), and the Metered Dose Inhaler and Spray manufacturing facilities. BPL is the first Bangladeshi company to receive this regulatory approval from TGA, Australia through a stringent facility audit process. With an overall pharmaceutical market of around US 10 billion dollars, Australia is one of the richest pharmaceutical markets in the Asia-Pacific region and the 13th largest in the world.”

“On 13 October, 2008 Beximco Pharmaceuticals Ltd. (‘BPL’ or the ‘Company’), the leading edge pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh has commenced exports to Chile, after receiving marketing authorization for a number of products from ‘Instituto de Salud Publica de Chile’ (Drug Regulatory authority in Chile). With this, BPL has become the first Bangladeshi pharmaceutical company to obtain product registration in any Latin American country.”

“On November 14, 2008 Beximco Pharmaceuticals Ltd. (‘BPL’ or the ‘Company’), the leading pharmaceutical manufacturer and the largest pharmaceutical exporter from Bangladesh, announces the achievement of a milestone today following the receipt of approval from the Ministry of Health of Gulf Cooperation Council (GCC) countries for BPL to commence export of medicines into the GCC. BPL is the first company from Bangladesh to receive this approval.”

“On July 31, 2009 Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”), the leading Bangladeshi pharmaceutical manufacturer and largest pharmaceutical exporter from Bangladesh, is pleased to announce that it has received GMP Certificate for its facility from National Health Surveillance Agency (Anvisa) of Brazil. BPL is the first Bangladeshi company to receive this regulatory approval from Anvisa through a stringent facility audit process

Company Specific News

Quality and Control

Local Market Share

Dynamic Sales Strategies

Foreign Market

Focus on Least Developed Countries (LDCs)

Recommendation